NASDAQ:CDXS - Codexis Stock Price, News, Headlines & Rumors

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Codexis, Inc. (NASDAQ:CDXS) posted its earnings results on Wednesday, August, 8th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.13) by $0.06. The biotechnology company earned $13.54 million during the quarter, compared to analysts' expectations of $11.87 million. Codexis had a negative net margin of 29.83% and a negative return on equity of 61.93%. View Codexis' Earnings History.

Codexis is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Codexis.

4 analysts have issued 1 year price objectives for Codexis' shares. Their forecasts range from $11.00 to $18.00. On average, they anticipate Codexis' share price to reach $14.25 in the next year. This suggests that the stock has a possible downside of 5.3%. View Analyst Price Targets for Codexis.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Codexis.

Some companies that are related to Codexis include Sensient Technologies (SXT), Westlake Chemical Partners (WLKP), Renewable Energy Group (REGI), Green Plains (GPRE), FutureFuel (FF), Green Plains Partners (GPP), REX American Resources (REX), Amyris (AMRS), Sino United Worldwide Consolidated (SUIC), Pacific Ethanol (PEIX), Tantech (TANH), CTD Holdings, Inc. Class A Common Stock (CTDH), Wave Sync (WAYS), Aemetis (AMTX) and Gevo (GEVO).

News coverage about CDXS stock has trended somewhat positive this week, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Codexis earned a media and rumor sentiment score of 0.13 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 45.69 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Codexis.

Codexis' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.39%), Baillie Gifford & Co. (4.97%), Opaleye Management Inc. (3.27%), Wells Fargo & Company MN (2.53%), Prescott Group Capital Management L.L.C. (2.22%) and First Light Asset Management LLC (1.57%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Michael D Aldridge, Pam P Cheng, Patrick Y Yang, Thomas R Baruch, Ventures Fund Vii LP Vivo, Ventures Vii Affiliates F Vivo and Vivo Ventures Vii, Llc. View Institutional Ownership Trends for Codexis.

CDXS stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP, Cortina Asset Management LLC, Prescott Group Capital Management L.L.C., Comprehensive Portfolio Management LLC, EAM Investors LLC and Bradley Foster & Sargent Inc. CT. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Michael D Aldridge, Pam P Cheng, Patrick Y Yang, Thomas R Baruch and Ventures Vii Affiliates F Vivo. View Insider Buying and Selling for Codexis.

CDXS stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Baillie Gifford & Co., First Light Asset Management LLC, Wells Fargo & Company MN, Alambic Investment Management L.P., Victory Capital Management Inc. and Swiss National Bank. View Insider Buying and Selling for Codexis.

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CDXS stock can currently be purchased for approximately $15.05.

Codexis has a market capitalization of $802.68 million and generates $50.02 million in revenue each year. The biotechnology company earns $-22,990,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Codexis employs 116 workers across the globe.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]